A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants

Inclusion Criteria: For all subjects: * Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m\^2 (both inclusive) * Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective For subjects with hepatic impairment: * Subjects with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan * Subjects with hepatic impairment (Child Pugh A or B) * Subjects with stable liver disease in the last 2 months For healthy subjects: * Mean age and body weight in the control group and in the two groups with hepatic impairment (Child Pugh A and B) should not vary by more than ± 10 years and ± 10 kg * Gender matched Exclusion Criteria: For all subjects: * Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor * Medical history of Kock pouch (ileostomy after proctocolectomy) * Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal * Known gastrointestinal (GI) disorders (eg stomach ulcers, duodenal ulcers, GI bleeding) or inflammatory bowel disease (eg Crohn's disease, ulcerative colitis) * Febrile illness within 1 week prior to admission to study center * Relevant diseases within the last 4 weeks prior to admission to study center * Known severe allergies, non-allergic drug reactions, or multiple drug allergies * Known hypersensitivity to the study drugs (active substances or excipients of the preparations) * Subjects with diagnosed malignancy within the past 5 years For subjects with hepatic impairment: * Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring anti-arrhythmic treatment * Evidence of hepatic encephalopathy related to chronic liver disease \> grade 2 (exclusion by Number Connection Test (NCT)) * Subjects with percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to study drug administration * History of bleeding within the past 3 months * Thrombotic disorder * Subjects with diabetes mellitus with a glycohemoglobin A1c (HbA1c) \>10% * Severe ascites of more than 6 L (estimated by ultrasound) * Subjects with primary and secondary biliary cirrhosis * Subjects with sclerosing cholangitis * Failure of any other major organ system other than the liver * Severe infection, malignancy, or psychosis, or any clinically significant illness within 4 weeks prior to study drug administration For healthy subjects: * Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal * Subjects with conspicuous findings in medical history or pre-study examination * A history of relevant diseases of vital organs, the central nervous system, or other organs